💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Lorazepam

CHEMBL580 Phase 4 Approuvé Small molecule
Half-Life
10-20 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
321.2 g/mol
LogP
2.4
Phase
4

A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

Masse moléculaire

321,1580 g/mol

LogP

2,40

TPSA

61,70 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pancreatic Cancer Bladder Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Hypertension Major Depressive Disorder Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

Classes de médicaments

N — N - Nervous System

Mécanisme d'action

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

Pharmacokinetics (PK)

Half-Life 10-20 hours

Pharmacodynamics (PD)

Mécanisme

Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O

                

                

                
                

                    
InChI

                    
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H10Cl2N2O2

                    

                    
                    

                        
HBD / HBA

                        
2 / 3

                    

                    
                    

                        
Liaisons Rotatives

                        
1

                    

                    
                    
                    

                        
Atomes Lourds

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A benzodiazepine used to treat anxiety disorders, status epilepticus, insomnia, and agitation, and studied as a sedative in critically ill patients. It enhances GABA activity in the brain, producing calming, sedating, and anticonvulsant effects.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting benzodiazepine enhancing GABA-A receptor chloride conductance.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Lorazepam: Half-life: 10-20 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Lorazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL580.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3958.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.